[February 13, 2014]

Research and Markets: Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Existing Angiogenics Retain Dominance Though High Unmet Need Remains

Research and Markets (http://www.researchandmarkets.com/research/2vs885/macular) has announced the addition of the "Asia-Pacific Macular Degeneration Therapeutics Market to 2019" report to their offering.

Asia-Pacific Macular Degeneration Therapeutics Market to 2019 covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. The authors analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012.

The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period.

Key Topics Covered:

1. Tables & Figures

2 Introduction

3 Marketed Products

3.1 Therapeutic Landscape

3.1.1 Lucentis (ranibizumab) - Novartis AG/Roche (Genentech)

3.1.2 Eylea (aflibercept) - Regeneron Pharmaceuticals/Bayer Healthcare

3.1.3 Avastin (bevacizumab) - Genentech (Roche)

3.1.4 Macugen (pegaptanib sodium) - Valeant Pharmaceuticals/Pfizer

3.1.5 Visudyne (verteporfin injection) - Novartis AG

3.1.6 Triamcinolone Acetonide

3.2 Comparative Efficacy and Safety

4 Pipeline for Disease

5 Market Forecast to 2019

6 Deals and Strategic Consolidations

6.1 Deals Analysis

6.2 Major Co-development Deals

6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR

6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners

6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD (News - Alert)

6.2.4 Alcon Enters into Collaboration with AstraZeneca

6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429

6.3 Major Licensing Deals

6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy

6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners

6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma

6.3.4 Lpath Enters into Licensing Agreement with Pfizer

6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Appendix

For more information visit http://www.researchandmarkets.com/research/2vs885/macular

[ Back To TMCnet.com's Homepage ]